Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY (LLY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 02:01pm CET

(Reuters) - Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

Valeurs citées dans l'article
ChangeLast1st jan.
ELI LILLY AND COMPANY -1.38% 77.86 Delayed Quote.-8.80%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
01:21pELI LILLY AND : Survey Reveals Many People with Migraine Live with Pain Nearly H..
PU
02/19AAD 2018 : Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in..
PU
02/16ELI LILLY AND : Integrating diabetes evidence into practice
PU
02/15ELI LILLY AND : New Biotechnology and Bioengineering Findings from Eli Lilly and..
AQ
02/14ELI LILLY AND : Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Pro..
PU
02/14ELI LILLY AND : Rediscovering My Purpose
PU
02/14ELI LILLY AND COMPANY : Free Research Report as Eli Lilly’s Quarterly Revenue Ju..
AC
02/14ELI LILLY AND COMPANY : ex-dividend day
FA
02/13ELI LILLY AND : Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ix..
PU
02/12ELI LILLY AND : Indiana city in jeopardy of losing animal health business
AQ
More news
News from SeekingAlpha
07:09aLilly's Taltz shows treatment benefit in genital psoriasis study 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/143 THINGS IN BIOTECH YOU SHOULD LEARN : February 13, 2018 
02/14YOUR DAILY PHARMA SCOOP : Akebia Update, Rexahn Data, Concert Commences Enrollme.. 
02/13Hutchison China completes enrollment in late-stage study of fruquintinib in t.. 
Financials ($)
Sales 2018 23 390 M
EBIT 2018 6 140 M
Net income 2018 4 748 M
Debt 2018 8 036 M
Yield 2018 2,91%
P/E ratio 2018 17,75
P/E ratio 2019 16,13
EV / Sales 2018 4,06x
EV / Sales 2019 4,00x
Capitalization 86 953 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 91,6 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Jan M. Lundberg Executive Vice President-Science & Technology
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-8.80%86 953
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359